Tianjin Hoyotek Biomedical Co., Ltd. was established in 2020 and is located in the Tianjin Port Free Trade Zone. The company is a nationally recognized high-tech enterprise, with its core focus on the research, development, and industrialization of innovative antibody therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and stroke therapeutic antibodies and vaccines.

The company has assembled a professional team composed of university doctoral supervisors, seasoned pharmaceutical R&D experts, and IVD industry professionals. Centered on the three core pathological mechanisms of neurodegenerative diseases, Hoyotek has built a proprietary pipeline targeting novel biomarkers including APOE-HSPG, AβpE3-42, and CD44V10—distinctively steering clear of the homogeneous and highly competitive R&D landscape prevalent in the domestic industry.

The company has achieved key technological breakthroughs in blood-brain barrier (BBB) delivery and antibody humanization, and has established an integrated preclinical R&D platform. Multiple lead antibody candidates have successfully completed mouse efficacy validation and are now approaching the clinical trial application stage.

Leveraging its in-house protein expression and magnetic bead labeling platforms, Hoyotek maintains full self-sufficiency in the production of antigens and antibodies—core raw materials essential to its pipeline. This vertical integration significantly reduces costs while ensuring complete autonomy and control over the R&D and supply chain.

The company's wholly-owned subsidiary, Homorn, provides comprehensive CRO/CDMO services for IVD and medical device development. Internally, it supports the compliance filing of companion diagnostics; externally, it expands business opportunities and generates complementary revenue streams, reinforcing the parent company's integrated service ecosystem.

In the IVD sector, Hoyotek has established a robust and sustainable revenue base, leveraging chemiluminescence and POCT technologies to commercialize over 100 product variants. The company holds more than 90 domestic registration certificates and over 180 CE certifications. Its neurology-focused testing portfolio ranks among the industry's most comprehensive, with products distributed across both domestic and international markets, generating steady cash flow that continuously supports the company's therapeutic antibody R&D programs.

In 2024, Hoyotek successfully closed a Pre-A financing round exceeding RMB 10 million, with the proceeds exclusively allocated to Alzheimer's disease antibody development and clinical evaluation.

Operating under a tripartite business model—innovative antibody therapeutics as the core driver, CRO services as a supporting pillar, and diagnostic reagents as the financial foundation—Hoyotek leverages its proprietary technologies to build formidable barriers to entry, accelerates the industrialization of biopharmaceuticals, and represents a compelling investment opportunity in the field of neurodegenerative disease therapeutics.